In their study, Katsu et al. established a rat model of NMO by administering AQP4-Abs, and they investigated the possibility that the prophylactic administration of RGMa-Mab has a possible disease-modifying effect on blood–spinal cord barrier (BSCB) dysfunction [14]. Here, AQP4 is linked to neuromyelitis optica.